Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.

<h4>Background</h4>Reports on metabolic syndrome in nephroblastoma and neuroblastoma survivors are scarce. Aim was to evaluate the occurrence of and the contribution of treatment regimens to the metabolic syndrome.<h4>Patients and methods</h4>In this prospective study 164 sub...

Full description

Bibliographic Details
Main Authors: Marjolein van Waas, Sebastian J C M M Neggers, Hein Raat, Caroline M van Rij, Rob Pieters, Marry M van den Heuvel-Eibrink
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23251703/pdf/?tool=EBI
id doaj-8ffadfb96ee947ea9b104ad69a00df51
record_format Article
spelling doaj-8ffadfb96ee947ea9b104ad69a00df512021-03-03T23:56:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01712e5223710.1371/journal.pone.0052237Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.Marjolein van WaasSebastian J C M M NeggersHein RaatCaroline M van RijRob PietersMarry M van den Heuvel-Eibrink<h4>Background</h4>Reports on metabolic syndrome in nephroblastoma and neuroblastoma survivors are scarce. Aim was to evaluate the occurrence of and the contribution of treatment regimens to the metabolic syndrome.<h4>Patients and methods</h4>In this prospective study 164 subjects participated (67 adult long-term nephroblastoma survivors (28 females), 36 adult long-term neuroblastoma survivors (21 females) and 61 control subjects (28 females)). Controls were recruited cross-sectionally. Waist and hip circumference as well as blood pressure were measured. Body composition and abdominal fat were assessed by dual energy X-ray absorptiometry (DXA-scan). Laboratory measurements included fasting triglyceride, high density lipoprotein-cholesterol (HDL-C), glucose, insulin, low-density lipoprotein-cholesterol (LDL-C) and free fatty acids (FFA) levels.<h4>Results</h4>Median age at follow-up was 30 (range 19-51) years in survivors and 32 (range 18-62) years in controls. Median follow-up time in survivors was 26 (6-49) years. Nephroblastoma (OR = 5.2, P<0.0001) and neuroblastoma (OR 6.5, P<0.001) survivors had more components of the metabolic syndrome than controls. Survivors treated with abdominal irradiation had higher blood pressure, triglycerides, LDL-C, FFA and lower waist circumference. The latter can not be regarded as a reliable factor in these survivors as radiation affects the waist circumference. When total fat percentage was used as a surrogate marker of adiposity the metabolic syndrome was three times more frequent in abdominally irradiated survivors (27.5%) than in non-irradiated survivors (9.1%, P = 0.018).<h4>Conclusions</h4>Nephroblastoma and neuroblastoma survivors are at increased risk for developing components of metabolic syndrome, especially after abdominal irradiation. We emphasize that survivors treated with abdominal irradiation need alternative adiposity measurements for assessment of metabolic syndrome.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23251703/pdf/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Marjolein van Waas
Sebastian J C M M Neggers
Hein Raat
Caroline M van Rij
Rob Pieters
Marry M van den Heuvel-Eibrink
spellingShingle Marjolein van Waas
Sebastian J C M M Neggers
Hein Raat
Caroline M van Rij
Rob Pieters
Marry M van den Heuvel-Eibrink
Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
PLoS ONE
author_facet Marjolein van Waas
Sebastian J C M M Neggers
Hein Raat
Caroline M van Rij
Rob Pieters
Marry M van den Heuvel-Eibrink
author_sort Marjolein van Waas
title Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
title_short Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
title_full Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
title_fullStr Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
title_full_unstemmed Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
title_sort abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description <h4>Background</h4>Reports on metabolic syndrome in nephroblastoma and neuroblastoma survivors are scarce. Aim was to evaluate the occurrence of and the contribution of treatment regimens to the metabolic syndrome.<h4>Patients and methods</h4>In this prospective study 164 subjects participated (67 adult long-term nephroblastoma survivors (28 females), 36 adult long-term neuroblastoma survivors (21 females) and 61 control subjects (28 females)). Controls were recruited cross-sectionally. Waist and hip circumference as well as blood pressure were measured. Body composition and abdominal fat were assessed by dual energy X-ray absorptiometry (DXA-scan). Laboratory measurements included fasting triglyceride, high density lipoprotein-cholesterol (HDL-C), glucose, insulin, low-density lipoprotein-cholesterol (LDL-C) and free fatty acids (FFA) levels.<h4>Results</h4>Median age at follow-up was 30 (range 19-51) years in survivors and 32 (range 18-62) years in controls. Median follow-up time in survivors was 26 (6-49) years. Nephroblastoma (OR = 5.2, P<0.0001) and neuroblastoma (OR 6.5, P<0.001) survivors had more components of the metabolic syndrome than controls. Survivors treated with abdominal irradiation had higher blood pressure, triglycerides, LDL-C, FFA and lower waist circumference. The latter can not be regarded as a reliable factor in these survivors as radiation affects the waist circumference. When total fat percentage was used as a surrogate marker of adiposity the metabolic syndrome was three times more frequent in abdominally irradiated survivors (27.5%) than in non-irradiated survivors (9.1%, P = 0.018).<h4>Conclusions</h4>Nephroblastoma and neuroblastoma survivors are at increased risk for developing components of metabolic syndrome, especially after abdominal irradiation. We emphasize that survivors treated with abdominal irradiation need alternative adiposity measurements for assessment of metabolic syndrome.
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23251703/pdf/?tool=EBI
work_keys_str_mv AT marjoleinvanwaas abdominalradiotherapyamajordeterminantofmetabolicsyndromeinnephroblastomaandneuroblastomasurvivors
AT sebastianjcmmneggers abdominalradiotherapyamajordeterminantofmetabolicsyndromeinnephroblastomaandneuroblastomasurvivors
AT heinraat abdominalradiotherapyamajordeterminantofmetabolicsyndromeinnephroblastomaandneuroblastomasurvivors
AT carolinemvanrij abdominalradiotherapyamajordeterminantofmetabolicsyndromeinnephroblastomaandneuroblastomasurvivors
AT robpieters abdominalradiotherapyamajordeterminantofmetabolicsyndromeinnephroblastomaandneuroblastomasurvivors
AT marrymvandenheuveleibrink abdominalradiotherapyamajordeterminantofmetabolicsyndromeinnephroblastomaandneuroblastomasurvivors
_version_ 1714811061381627904